Mutational activation of ErbB family receptor tyrosine kinases: Insights into mechanisms of signal transduction and tumorigenesis

BioEssays

Volumn 29, Issue 6, 2007, Pages 558-565

  Riese II, David J ^a,c   Gallo, Richard M ^a   Settleman, Jeffrey ^b  

^a PURDUE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

CARCINOGENESIS; DIMERIZATION; GENE MUTATION; HUMAN; LIGAND BINDING; MUTATIONAL ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

ENZYME ACTIVATION; HUMANS; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 34250216633     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20582     Document Type: Review

References (65)

1. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
2. Kamath S, Buolamwini JK. 2006. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 26:569-594.
3. Lemmon MA. 2003. The EGF receptor family as therapeutic targets in breast cancer. Breast Dis 18:33-43.
4. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, et al. 2005. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25:7734-7742.
5. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, et al. 2003. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507-517.
6. Cho HS, Leahy DJ. 2002 Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330-1333.
7. Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ. 2005. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 102:15024-15029.
8. Ozcan F, Klein P, Lemmon MA, Lax I, Schlessinger J, 2006. On the nature of low- and high-affinity EGF receptors on living cells. Proc Natl Acad Sci USA 103:5735-5740.
9. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
10. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. 1988. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. Embo J 7:1647-1651.
11. Honegger AM, Kris RM, Ullrich A, Schlessinger J. 1989. Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc Natl Acad Sci USA 86:925-929.
12. Honegger AM, Schmidt A, Ullrich A, Schlessinger J. 1990. Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells. Mol Cell Biol 10:4035-4044.
13. Lammers R, Van Obberghen E, Ballotti R, Schlessinger J, Ullrich A. 1990. Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. J Biol Chem 265:16886-16890.
14. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, et al. 2003. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495-505.
15. Gilmore JL, Gallo RM, Riese DJ 2nd. 2006. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J 396:79-88.
16. Jones JT, Akita RW, Sliwkowski MX. 1999. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231.
17. Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, et al. 1998. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 18:6090-6101.
18. Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, et al. 1999. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 19:8695.
19. Gilmore JL, Riese DJ 2nd. 2004. secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res 14:589-602.
20. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS, 2001. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12:745-760.
21. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, et al. 1997. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324:855-861.
22. Fernandes H, Cohen S, Bishayee S. 2001. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 276: 5375-5383.
23. Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, et al. 2004. The tumor-specific de 2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23: 6095-6104.
24. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. 2006. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Med 3: e485.
25. Boerner JL, Danielsen A, Maihle NJ. 2003. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res 284:111-121.
26. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, et al. 1984. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527.
27. Penington DJ, Bryant I, Riese DJ 2nd. 2002. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 13:247-256.
28. Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, et al. 2003. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 192:67-74.
29. Burke CL, Stern DF. 1998. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol 18:5371-5379.
30. Siegel PM, Dankort DL, Hardy WR, Muller WJ. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068-7077.
31. Mendrola JM, Berger MB, King MC, Lemmon MA. 2002. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 277:4704-4712.
32. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. 1982. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28:865-871.
33. Bargmann CI, Hung MC, Weinberg RA. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 Cell 45:649-657.
34. Smith SO, Smith CS, Bormann BJ. 1996. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat Struct Biol 3:252-258.
35. Smith SO, Smith C, Shekar S, Peersen O, Ziliox M, et al. 2002. Transmembrane interactions in the activation of the Neu receptor tyrosine kinase. Biochemistry 41:9321-9332.
36. Bargmann CI, Weinberg RA. 1988. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 85:5394-5398.
37. Bargmann CI, Weinberg RA. 1988. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. Embo J 7:2043-2052.
38. Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF. 1997. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 14:687-696.
39. Miloso M, Mazzotti M, Vass WC, Beguinot L. 1995. SHC and GRB-2 are constitutively by an epidermal growth factor receptor with a point mutation in the transmembrane domain. J Biol Chem 270:19557-19562.
40. Vidal GA, Clark DE, Marrero L, Jones FE. 2007. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 26:462-466.
41. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
42. Sordella R, Bell DW, Haber DA, Settleman J, 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167.
43. Calvo E, Rowinsky EK. 2004. Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. Clinical lung cancer 6 Suppl 1:S35-S42.
44. Johnson BE, Janne PA. 2005. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65: 7525-7529.
45. Arteaga CL. 2006. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer cell 9:421-423.
46. Ji H, Sharpless NE, Wong KK. 2006. EGFR targeted therapy: view from biological standpoint. Cell cycle (Georgetown, Tex) 5:2072-2076.
47. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, et al. 2005. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974.
48. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, et al. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313.
49. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2:e73
50. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, et al. 2005. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65:7096-7101.
51. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, et al. 2006. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287.
52. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, et al. 2005. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316.
53. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, et al. 2004. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526.
54. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, et al. 2006. Somatic mutations of the ERBB4 kinase domain in human cancers. International journal of cancer 118:1426-1429.
55. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, et al. 2005. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646.
56. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, et al. 2006. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell 10:25-38.
57. Schulze WX, Deng L, Mann M. 2005. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:0008.
58. Grovdal LM, Stang E, Sorkin A, Madshus IH. 2004. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300:388-395.
59. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, et al. 2002. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. Embo J 21:303-313.
60. Jiang X, Huang F, Marusyk A, Sorkin A. 2003. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Molecular biology of the cell 14:858-870.
61. Huang F, Sorkin A. 2005. Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Molec Biol Cell 16:1268-1281.
62. Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ 2nd. 2006. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun 349:372-382.
63. Komuro A, Nagai M, Navin NE, Sudol M. 2003. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278:33334-33341.
64. Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, et al. 2004. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294:469-479.
65. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, et al. 2005. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65:6764-6772.